| Literature DB >> 33170927 |
Marieke M van der Zalm1, Juanita Lishman2, Lilly M Verhagen2,3, Andrew Redfern2, Liezl Smit2, Mikhail Barday2, Dries Ruttens2,4, A'ishah da Costa2, Sandra van Jaarsveld2, Justina Itana2, Neshaad Schrueder5, Marije Van Schalkwyk6, Noor Parker2, Ilse Appel2, Barend Fourie2, Mathilda Claassen7, Jessica J Workman1, Pierre Goussard2, Gert Van Zyl7, Helena Rabie2.
Abstract
BACKGROUND: Children seem relatively protected from serious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease, but little is known about children living in settings with high tuberculosis and human immunodeficiency virus (HIV) burden. This study reflects clinical data on South African children with SARS-CoV-2.Entities:
Keywords: COVID-19; MIS-C; children; respiratory virus infections; sub-Saharan Africa
Mesh:
Year: 2021 PMID: 33170927 PMCID: PMC7717210 DOI: 10.1093/cid/ciaa1666
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 20.999
Characteristics of Inpatient and Outpatient Children With Positive Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Test
| Characteristic | No. | All (N = 159) | Outpatients (n = 97) | Inpatients (n = 62) |
|
|---|---|---|---|---|---|
| Sex, male | 159 | 88 (55.3) | 53 (54.6) | 35 (56.5) | .87 |
| Age, mo, median (IQR) | 159 | 48.0 (12.0–106.0) | 81.0 (34.5–120.5) | 13.5 (1.8–43.5) | <.01 |
| Age group | 159 | <.01 | |||
| 0–3 mo | 23 (14.5) | 4 (4.1) | 19 (30.6) | ||
| 3–12 mo | 18 (11.3) | 7 (7.2) | 11 (17.7) | ||
| 1–5 y | 46 (28.9) | 25 (25.8) | 21 (33.9) | .01 | |
| >5 y | 72 (45.3) | 61 (62.9) | 11 (17.7) | ||
| Comorbidities | |||||
| Any comorbidities | 159 | 33 (20.8) | 4 (4.1) | 29 (46.8) | NA |
| Prematurity | … | NR | 8 (12.9) | ||
| Hematology | 2 (1.3) | 0 | 2 (3.2) | ||
| Oncology | 6 (3.8) | 1 (1.0) | 5 (8.1) | ||
| HIV infection | 2 (1.3) | … | 2 (3.6) | ||
| Tuberculosis | 2 (1.3) | … | 2 (3.2) | ||
| Cardiac | 2 (1.3) | … | 2 (3.2) | ||
| Gastrointestinal | 2 (1.3) | … | 2 (3.2) | ||
| Asthma | 4 (2.5) | 3 (3.1) | 1 (1.6) | ||
| Other | 7 (4.4) | … | 7 (11.3) | ||
| HIV exposed | 32 | … | NR | 13 (40.6) | NA |
| Symptoms | |||||
| Symptomatic | 159 | 81 (50.9) | 70 (72.2) | 51 (82.3) | .20 |
| Cough | 159 | 72 (45.3) | 58 (59.8) | 22 (35.5) | .04 |
| Fever/ history of fever | 159 | 50 (32.1) | 31 (32.0) | 22 (35.5) | .73 |
| Sore throat | 88a | 18/88 (20.5) | 16/72 (22.2) | 2/16 (12.5) | .03 |
| Tight chest | 159 | 27 (17.0) | 7 (7.2) | 20 (32.2) | <.01 |
| Gastrointestinal symptoms | |||||
| Abdominal pain | 16a | … | NR | 10/16 (62.5) | |
| Diarrhea | 159 | 22 (13.8) | 10 (10.3) | 12 (19.4) | .03 |
| Vomiting | 159 | 18 (11.3) | 2 (2.1) | 15 (24.1) | <.01 |
| Anosmia or ageusia | 88a | 9/88 (10.2) | 9/72 (12.5) | 0 | |
| Headache | 88a | 15/88 (17.0) | 14/72 (19.4) | 1/16 (6.3) | |
| Convulsions | 159 | 5 (3.1) | 0 | 5 (8.1) | |
| Rashb | 159 | 6 (3.8) | 0 | 6 (9.7) |
Data are presented as No. (%) unless otherwise indicated. Pearson χ 2 test was used to compare the differences between inpatients and outpatients. The Yates continuity correction was used if the expected cell size was <5.
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable; NR, not recorded.
aCorrected for children able to report these symptoms, >3 years of age.
bRashes included 1 petechial rash, 2 macular papular rashes, 1 erythematous rash, and 2 vesicular rashes.
Characteristics of Symptomatic Hospitalized Children With Positive Severe Acute Respiratory Syndrome Coronavirus 2 Molecular Test, by Age Group
| Characteristic | All (N = 51) | All Ages | 0–3 mo (n = 16) | >3–12 mo (n = 7) | >1–5 y (n = 18) | >5 y (n = 10) |
|
|---|---|---|---|---|---|---|---|
| Sex, male | 51 | 28 (54.9) | 10 (62.5) | 4 (57.1) | 8 (44.4) | 6 (60.0) | .63 |
| BCG vaccination history or scar | 36 | 34 (94.4) | 14 (87.5) | 3 (42.9) | 11 (61.1) | 6 (60.0) | .53 |
| WAZ, median (IQR)a | 46 | –0.5 (–1.6 to 0.3) | –0.7 (–1.7 to 0.5) | –2.1 (–6.0 to –0.3) | –0.3 (–0.5 to 0.3) | –0.3 (–1.9 to 0.8) | .16 |
| HIV infection | 46 | 1 (2.2) | 1 (6.3) | 0 | 0 | 0 | |
| HEU | 32 | 11 (34.4) | 7 (43.8) | 1 (14.3) | 3 (16.6) | 0 | .05 |
| Premature | 51 | 7 (13.7) | 2 (12.5) | 3 (42.9) | 1 (5.5) | 1 (10.0) | |
| Hematology | 51 | 1 (1.9) | 0 | 0 | 1 (5.5) | 0 | |
| Oncology | 51 | 2 (3.9) | 0 | 0 | 1 (5.5) | 1 (10.0) | |
| Clinical presentation | |||||||
| Respiratory | 51 | 24 (47.1) | 11 (52.6) | 5 (71.4) | 6 (33.3) | 2 (20.0) | |
| URTI | 3 (5.9) | 0 | 1 (14.3) | 2 (11.1) | 0 | ||
| LRTI | 21 (41.2) | 11 (69.8) | 4 (57.1) | 4 (22.2) | 2 (20.0) | ||
| Gastrointestinal | 9 (17.6) | 1 (10.5) | 1 (14.3) | 3 (16.6) | 4 (40.0) | ||
| Infectious | 7 (13.7) | 2 (10.5) | 0 | 4 (22.2) | 1 (10.0) | ||
| Neurology | 6 (11.8) | 1 (5.3) | 1 (14.3) | 3 (16.6) | 1 (10.0) | ||
| Cardiovascular | 3 (5.9) | 1 (5.3) | 0 | 1 (5.5) | 1 (10.0) | ||
| Other | 2 (3.9) | 0 | 0 | 1 (5.5) | 1 (10.0) | ||
| Hospital course | |||||||
| Respiratory support | 51 | 25 (49.0) | 13 (81.3) | 4 (57.1) | 6 (33.3) | 2 (20.0) | .02 |
| Duration of respiratory support, d, median (min–max) | 48 | 6.0 (1.0–21.0) | 7.0 (2.0–21.0) | 6.0 (1–13.0) | 1.0 (1.0–21.0) | 3.5 (1.0–6.0) | .10 |
| NPO2 | 51 | 24 (47.1) | 13 (81.3) | 3 (42.9) | 6 (33.3) | 2 (20.0) | .02 |
| NIRS | 51 | 14 (27.5) | 7 (43.8) | 3 (42.9) | 3 (16.7) | 1 (10.0) | .14 |
| IPPV | 51 | 5 (9.8) | 2 (12.5) | 0 | 2 (11.1) | 1 (10.0) | |
| PICU admission | 51 | 11 (23.5) | 3 (18.8) | 2 (28.6) | 3 (16.7) | 3 (30.0) | |
| Outcome | |||||||
| LOS, d, median (IQR) | 51 | 5.0 (2.0–9.0) | 7.0 (4.0–16.0) | 5.0 (1.5–9.5) | 3.0 (1.0–5.5) | 7.0 (1.5–8.5) | .06 |
| Died | 51 | 1 (2.0) | 1 (6.3) | 0 | 0 | 0 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: d, days; HEU, human immunodeficiency virus exposed but uninfected; HIV, human immunodeficiency virus; IPPV, intermittent positive pressure ventilation; IQR, interquartile range; LOS, length of stay; LRTI, lower respiratory tract infection; NIRS, noninvasive respiratory support; NPO2, nasal prong oxygen; PICU, pediatric intensive care unit; URTI, upper respiratory tract infection; WAZ, weight-for-age z score.
aFor children older than 10 years (n = 5), we used the Centers for Disease Control and Prevention weight-for-age calculation in percentiles (59.0, 65.8, 68.5, 74.9, 76.0); see text.
Summary of Children Who Were Polymerase Chain Reaction Positive for Severe Acute Respiratory Syndrome Coronavirus 2 Admitted to the Pediatric Intensive Care Unit, by Age Group
| Admitted to PICU | All (N = 11) | Age <3 mo (n = 3 [27.3%]) | Age 3–12 mo (n = 2 [18.2%]) | Age >1–5 y (n = 3 [27.3%]) | Age >5 y (n = 3 [27.3%]) |
|---|---|---|---|---|---|
| PICU LOS, d, median (IQR) | 4.0 (1.0–8.0) | 5.0 (5.0–8.0) | 4.5 (2.0–7.0) | 4.0 (2.0–4.0) | 1.0 (1.0–4.0) |
| Indication for admission–pneumonia | 7 (58.3%) | 2 (66.7%) | 2 (100%) | 3 (100%) | 0 |
| Cardiac arrhythmia | 2 (16.7%) | 1 (33.3%): SVT (1) | 0 | 0 | 1 (33.3%): SVT with possible myocarditis (1) |
| Other | 3 (25.0%) | 0 | 0 | 2 (66.7%): Appendicitis/MIS-C (2) | |
| Underlying/concurrent illness | 7 (58.3%) | 3 (100%): HIV (1) WPW syndrome (1) PDA (1) | 2 (100%): Trisomy 21 with AVSD (1) Rickets (1) | 2 (50%): Tuberculosis (PTB and TBM) (1) Asthma (1) | 0 |
| Respiratory viruses other than SARS-CoV-2a | 5/6 (83.3%) | 1/1 (100%): CMV | 2/2 (100%): HRV/CMV (1) RSV (1) | 2/3 (66.7%): HRV (1) HRV/CMV (1) | 0 |
| Invasive ventilation | 4 (33.3%) | 1 (33.3%) | 0 | 2 (50.0%) | 1 (33.3%) |
| Noninvasive ventilation | 8 (66.7%) | 3 (100%) | 2 (100%) | 2 (50.0%) | 1 (33.3%) |
| Inotropic support | 4 (33.3%) | 2 (66.7%) | 0 | 0 | 2 (66.7%) |
| Steroids | 9 (75.0%) | 2 (66.7%) | 1 (50.0%) | 4 (100.0%) | 2 (66.7%) |
Abbreviations: AVSD, atrioventricular septal defect; CMV, cytomegalovirus; HIV, human immunodeficiency virus; HRV, human rhinovirus; IQR, interquartile range; LOS, length of stay; MIS-C, multisystem inflammatory syndrome in children; PDA, patent ductus arteriosus; PICU, pediatric intensive care unit; PTB, pulmonary tuberculosis; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SVT, supraventricular tachycardia; TBM, tuberculous meningitis; WPW, Wolf-Parkinson-White syndrome.
aA full respiratory panel was done in 6 of 12 children.